Preoperative [ 18F]FDG PET/CT predicts recurrence in patients with epithelial ovarian cancer

Journal of Gynecologic Oncology

Volumn 23, Issue 1, 2012, Pages 28-34

  Chung, Hyun Hoon ^a   Kwon, Hyun Woo ^a,b   Kang, Keon Wook ^a,b   Kim, Jae Weon ^a   Park, Noh Hyun ^a   Song, Yong Sang ^a,c   Kang, Soon Beom ^a  

^a Seoul National University   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

Distribution; Epithelial ovarian cancer; Recurrence; Standardized uptake value

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ANALYTICAL PARAMETERS; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORRELATION ANALYSIS; ENDOMETRIOID CARCINOMA; EPITHELIAL OVARY CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MIXED MULLERIAN TUMOR; MUCINOUS CARCINOMA; OVARY CANCER; PREOPERATIVE EVALUATION; PROGRESSION FREE SURVIVAL; STANDARDIZED UPTAKE VALUE; UMBILICUS;

EID: 84863234124     PISSN: 20050380     EISSN: 20050399     Source Type: Journal    
DOI: 10.3802/jgo.2012.23.1.28     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer sta tistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. th Annual Report on the Results of Treatment in Gynecologi cal Cancer. Int J Gynaecol Obstet 2006;95(Suppl 1):S161-92.
3. Park TW, Kuhn WC. Neoadjuvant chemotherapy in ovarian cancer. Expert Rev Anticancer Ther 2004;4:639-47.
4. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:1248-59.
5. Naik R, Nordin A, Cross PA, Hemming D, de Barros Lopes A, Monaghan JM. Optimal cytoreductive surgery is an independent prognostic indicator in stage IV epithelial ovarian cancer with hepatic metastases. Gynecol Oncol 2000;78:171-5.
6. Heintz AP, Hacker NF, Berek JS, Rose TP, Munoz AK, Lagasse LD. Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity. Obstet Gynecol 1986;67:783-8.
7. Prakash P, Cronin CG, Blake MA. Role of PET/CT in ovarian cancer. AJR Am J Roentgenol 2010;194:W464-70.
8. Chung HH, Kang WJ, Kim JW, Park NH, Song YS, Chung JK, et al. Role of [18F]FDG PET/CT in the assessment of suspect{stroke}ed recurrent ovarian cancer: correlation with clinical or histological findings. Eur J Nucl Med Mol Imaging 2007;
9. Kitajima K, Murakami K, Yamasaki E, Kaji Y, Fukasawa I, Inaba N, et al. Diagnostic accuracy of integrated FDG-PET/contrast-enhanced CT in staging ovarian cancer: comparison with enhanced CT. Eur J Nucl Med Mol Imaging 2008;35: 1912-20.
10. Dirisamer A, Schima W, Heinisch M, Weber M, Lehner HP, Haller J, et al. Detection of histologically proven peritoneal carcinomatosis with fused 18F-FDG-PET/MDCT. Eur J Radiol 2009;69:536-41.
11. Townsend DW, Beyer T. A combined PET/CT scanner: the path to true image fusion. Br J Radiol 2002;75(Spec No): S24-30.
12. Cormio G, Rossi C, Cazzolla A, Resta L, Loverro G, Greco P, et al. Distant metastases in ovarian carcinoma. Int J Gynecol Cancer 2003;13:125-9.
13. Avril N, Sassen S, Schmalfeldt B, Naehrig J, Rutke S, Weber WA, et al. Prediction of response to neoadjuvant chemo therapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol 2005;23:7445-53.
14. Nishiyama Y, Yamamoto Y, Kanenishi K, Ohno M, Hata T, Kushida Y, et al. Monitoring the neoadjuvant therapy response in gynecological cancer patients using FDG PET. Eur J Nucl Med Mol Imaging 2008;35:287-95.
15. Sironi S, Messa C, Mangili G, Zangheri B, Aletti G, Garavaglia E, et al. Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histologic findings. Radi ology 2004;233:433-40.
16. Kim S, Chung JK, Kang SB, Kim MH, Jeong JM, Lee DS, et al. [18F]FDG PET as a substitute for second-look laparotomy in patients with advanced ovarian carcinoma. Eur J Nucl Med Mol Imaging 2004;31:196-201.
17. Soussan M, Wartski M, Cherel P, Fourme E, Goupil A, Le Stanc E, et al. Impact of FDG PET-CT imaging on the decision making in the biologic suspicion of ovarian carcinoma recurrence. Gynecol Oncol 2008;108:160-5.
18. Chung HH, Kang WJ, Kim JW, Park NH, Song YS, Chung JK, et al. The clinical impact of [(18)F]FDG PET/CT for the management of recurrent endometrial cancer: correlation with clinical and histological findings. Eur J Nucl Med Mol Imaging 2008;35:1081-8.
19. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 1975;42:101-4.
20. Eisenkop SM, Spirtos NM, Lin WC. Optimal cytoreduction for advanced epithelial ovarian cancer: a commentary. Gynecol Oncol 2006;103:329-35.
21. Chi DS, Eisenhauer EL, Lang J, Huh J, Haddad L, Abu-Rustum NR, et al. What is the optimal goal of primary cytoreduct{stroke}ive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 2006;103:559-64.
22. Wimberger P, Lehmann N, Kimmig R, Burges A, Meier W Du Bois A, et al. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival: an exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol 2007;106:69-74.
23. Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Analysis of fact{stroke}ors impacting operability in stage IV ovarian cancer: rat{stroke}ionale use of a triage system. Gynecol Oncol 2007;105: 84-9.
24. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1992; 47:159-66.
25. Crawford SC, Vasey PA, Paul J, Hay A, Davis JA, Kaye SB. Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial. J Clin Oncol 2005;23:8802-11.